Michele Gaiotto

Neurofenix is the world’s leading Neuro-rehab Tech-enabled virtual care provider, establishing a new standard of care for neurological patients. We offer innovative at-home therapy services, powered by caring clinicians available virtually, giving stroke survivors the opportunity they need to make a comeback and live their lives again. To read more: https://neurofenix.com/

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

Delpor is a clinical stage life sciences company that utilizes innovative drug-delivery technologies in order to develop once-yearly therapies for chronic conditions. The Company’s lead product is a 6-12-month formulation of Risperidone (drug/device combination product) for the treatment of schizophrenia. Delpor is also pursuing 6-12 month formulations of other drugs targeting CNS conditions including Neuromuscular Diseases, Neurodegenerative Diseases, Addiction, and other disorders.

Multistrategy. Evergreen. Unconstrained. Three Peaks is a multistrategy investment firm built on the principle that flexibility is the ultimate hedge. Operating with an evergreen capital structure, we reject the constraints of rigid mandates to follow value wherever it lives—across time horizons and asset classes. We thrive in complexity. By maintaining the agility to move capital quickly during market dislocations, we capitalize on opportunities ranging from immediate tactical shifts to foundational, long-term structural plays. At our core, we believe that speed and conviction in complicated situations are the key differentiators for generating superior risk-adjusted returns. We dont just wait for the right cycle; we move capital to where we think the cycle is most favorable. Our Core Philosophy Anticipating Macro Shifts: Our edge lies in identifying structural changes before they become consensus. From early allocations in energy sectors driven by evolving capital return strategies to current opportunities in distressed environments, we position ourselves ahead of the curve. Thematic Flexibility: We rotate capital seamlessly between short-term tactical plays (1–3 years) and long-term structural themes, ensuring we are always optimized for the prevailing environment. Decisive Action: In "messy" or complicated situations, the ability to move capital quickly and with conviction is our key differentiator. Uncorrelated Returns: By looking where others arent, we build a diversified portfolio designed to deliver high expected returns with low correlation to broader markets.

Neurofenix is the world’s leading Neuro-rehab Tech-enabled virtual care provider, establishing a new standard of care for neurological patients. We offer innovative at-home therapy services, powered by caring clinicians available virtually, giving stroke survivors the opportunity they need to make a comeback and live their lives again. To read more: https://neurofenix.com/

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

Our product, Airgo™ is a patented, CE certified non-invasive proxy for spirometry, sleep disorder screening (OSA, CSA, AHI, RDI, sleep staging, Cheyne–Stokes) and ICU respiratory pattern detection. We are extending its application to Covid-19 critical patient care and management (correlating Respiratory Rate, Tidal Volume and FRC) crucial in respiratory distress monitoring (ARDS). Our area of expertise is strategic monitoring of respiration dynamics during sleep and daytime activity, providing precise breath metrics, automated scoring, and early indication of respiratory distress. We are actively involved in assisting physicians in Covid-19 patient remote monitoring.

HTH is a Private Venture Capital Investment Company backed by Entrepreneur in the Healthcare Sector. The company provides capital to Early to Mid Stage companies with breakthrough technologies in Life Sciences. The company invests internationally and focuses on Medtech, Biotech, Digital Health and related fields.